Asta Juzeniene

• Kristiansen, Sandra Kvarsvik; Dernjani, Nurtene Berisha; Bruland, Øyvind; Edin, Nina Frederike Jeppesen & Juzeniene, Asta (2026). A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [212Pb]Pb-FAPI-46. EJNMMI Radiopharmacy and Chemistry. 11(1). doi: 10.1186/s41181-026-00444-0. Full text in Research Archive
• Kristiansen, Sandra Kvarsvik; Shubin, Kirill; Zubrienė, Asta; Matulis, Daumantas; Dernjani, Nurtene Berisha & Juzenas, Petras [Show all 8 contributors for this article] (2026). Radiobiological investigations of a [212Pb]Pb-carbonic anhydrase IX-targeting small-molecule ligand in renal cell carcinoma and colorectal cancer models. International Journal of Radiation Biology. ISSN 0955-3002. 102(2). doi: 10.1080/09553002.2025.2595630. Full text in Research Archive Show summary

  Purpose Carbonic anhydrase IX (CAIX), overexpressed in multiple cancers but limited in normal tissue, is a promising target for radionuclide therapy. This study evaluates [212Pb]Pb-MKV-509, a novel DOTA-conjugated small-molecule ligand, for CAIX-targeted alpha therapy in preclinical renal carcinoma (SK-RC-52) and colorectal (HT-29) cancer models. Materials and methods [212Pb]Pb-MKV-509 was assessed for radiochemical purity and stability. Binding assays determined receptor density and dissociation constants. Clonogenic survival, flow cytometry (viability, DNA damage, cell cycle), and spheroid assays (cross-sectional area, doubling time) evaluated biological responses. An in vivo biodistribution study was performed in SK-RC-52 xenograft-bearing mice, with and without carbonic anhydrase pre-blocking using acetazolamide. Results [212Pb]Pb-MKV-509 exhibited high radiochemical purity (>96%) and stability for up to 48 h. Specific binding was higher in SK-RC-52 than in HT-29 cells. Treatment induced activity-dependent clonogenic inhibition, G2/M arrest, and DNA damage, with greater sensitivity observed in SK-RC-52 cells. Clonogenic survival was reduced by 50% at 3.4 kBq/mL (SK-RC-52) and 7.1 kBq/mL (HT-29). In spheroid models, 2.5–5.0 kBq/mL delayed growth and prolonged doubling time, indicating cross-fire effects. The biodistribution study revealed significant tumor uptake (4.7%IA/g at 2 h), along with high gastrointestinal accumulation. Pretreatment with acetazolamide partially reduced uptake in the stomach and intestines as well as in the tumor. Conclusions These findings highlight the potential of CAIX-targeted alpha therapy. CAIX expression and receptor density impact binding affinity and therapeutic response. The study demonstrates the importance of 3D tumor models in evaluating alpha-particle cross-fire effects. Further ligand optimization is warranted to enhance tumor specificity and minimize off-target uptake.

• Lindland, Kim; Westrøm, Sara; Dragovic, Srdan M.; Li, Ruth Gong; Malenge, Marion Masitsa & Ho, Betty [Show all 8 contributors for this article] (2025). Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. Molecular Cancer Therapeutics. ISSN 1535-7163. 24(9), p. 1415–1427. doi: 10.1158/1535-7163.mct-24-1060. Full text in Research Archive Show summary

  Protein tyrosine kinase 7 (PTK7), a receptor found in tumor-initiating cells, is expressed in various malignancies, including ovarian cancer. Whereas PTK7 has been explored as a target for antibody–drug conjugates, this study is the first to investigate its potential for targeted radionuclide therapy. We developed a murine monoclonal IgG1 antibody (mOI-1) using hybridoma technology and generated a chimeric version (chOI-1) with human IgG1 constant regions. A cell-based screening approach using a library of 6,100 cell surface proteins identified PTK7 as the target, confirmed by flow cytometry and surface plasmon resonance analyses. IHC showed strong PTK7 expression in ovarian cancer tissues, and in vitro studies demonstrated specific binding and internalization of OI-1 in the ovarian cancer cell line SKOV-3-luc. Biodistribution studies using 177Lu–DOTA–mOI-1 injected intravenously in xenograft mice with subcutaneous SKOV-3-luc revealed high tumor uptake and retention. Therapeutic efficacy was assessed by intraperitoneal treatment with 212Pb–TCMC–chOI-1 in an intraperitoneal xenograft model, showing significant tumor growth inhibition compared with nonradioactive controls. This study provides the first investigation of a PTK7-targeting antibody (OI-1) as an antibody–radionuclide conjugate (212Pb–labeled) in a preclinical model of intraperitoneal ovarian cancer. These results support further investigation of OI-1 as a candidate for targeted radionuclide therapy in PTK7-expressing cancers.

• Stenberg, Vilde Yuli; Liukaityte, Rugile; Kristiansen, Sandra Kvarsvik; Wangen-Riise, Rina; Kleinauskas, Andrius & Dunne, Victoria [Show all 7 contributors for this article] (2025). Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001. Scientific Reports. 16(1). doi: 10.1038/s41598-025-29785-7. Full text in Research Archive Show summary

  Targeted alpha therapy holds promise for treating advanced prostate cancer, but the interplay between prostate-specific membrane antigen (PSMA) expression, p53 status, and downstream cell fate remains poorly defined. This study evaluates the cytotoxic and cell cycle effects of the alpha-emitting radioligand [212Pb]Pb-AB001 in prostate cancer cell lines with differing PSMA expression and p53 status: C4-2 (PSMA+/TP53-wild-type) and PC-3 PIP (PSMA+++/ TP53-null). [212Pb]Pb-AB001 significantly inhibited proliferation and clonogenic survival in both cell lines in an activity-dependent manner. At 95% clonogenic inhibition, both cell lines exhibited G2-phase arrest, S-phase suppression and reduced mitotic entry on day 1. At higher activities, PC-3 PIP cells showed polyploidy, and features consistent with mitotic catastrophe and senescence. Cytotoxicity was more pronounced in C4-2 3D spheroid models than in 2D monolayers, suggesting contribution of crossfire and bystander effects. Total cell-bound activity, rather than added activity, better predicted radiotoxicity in both TP53-wild-type and TP53-null cell lines, indicating that its therapeutic effect is primarily governed by PSMA-mediated uptake rather than p53 status. These results support the therapeutic potential of [212Pb]Pb-AB001 across cells with varying TP53 status and suggest that combining [212Pb]Pb-AB001 with DNA repair or checkpoint inhibitors may enhance treatment efficacy.

• Lindland, Kim & Juzeniene, Asta (2025). Cytotoxicity of 212Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models. EJNMMI Radiopharmacy and Chemistry. 10(1). doi: 10.1186/s41181-025-00382-3. Full text in Research Archive Show summary

  Background Bladder cancer remains a significant global health challenge, with approximately 75% of cases presenting as non-muscle-invasive bladder cancer. Despite standard treatment with transurethral resection and intravesical Bacillus Calmette-Guérin immunotherapy, up to 40% of patients develop resistance or progress to muscle-invasive disease. Targeted alpha-emitting radionuclide therapy offers promising therapeutic potential through the selective delivery of high linear energy transfer radiation to tumor cells while minimizing damage to healthy tissues. PTK7 is overexpressed in various malignancies, including bladder cancer, and is therefore a viable therapeutic target. This study evaluated the preclinical efficacy of [212Pb]Pb-TCMC-chOI-1, a 212Pb-labeled antibody targeting PTK7, for targeted alpha-emitting radionuclide therapy in bladder cancer using 2D adherent cultures (clonogenic assay) and 3D multicellular spheroid models (spheroid growth inhibition). Results PTK7 expression analysis revealed varying antigen densities across five bladder cancer cell lines, ranging from approximately 10,000 to 70,000 sites per cell. The chimeric anti-PTK7 antibody demonstrated apparent equilibrium dissociation constants of 10–44 nM with moderate binding affinity suitable for therapeutic applications. [212Pb]Pb-TCMC-chOI-1 treatment resulted in activity- and time-dependent cytotoxicity, with enhanced sensitivity observed in cell lines with higher PTK7 levels. In clonogenic assays, the activity concentration required for 50% growth reduction was 48–74 kBq/mL, corresponding to 22–51 bound and 9–16 internalized 212Pb atoms per cell. In 3D models, similar therapeutic effects were observed despite significantly lower activities (values of approximately 1 and 30 kBq/mL for KU-19–19 and 647-V cells, respectively), suggesting a more pronounced cross-fire effect. Flow cytometry demonstrated treatment-induced DNA damage, cell cycle perturbations and cell death, with response patterns correlating with overall treatment sensitivity. RT-112 and KU-19–19 cells showed superior responses compared to 647-V and T-24 cells, consistent with their higher PTK7 expression. Conclusions These findings support PTK7 as a therapeutic target for bladder cancer and demonstrate the potential of [212Pb]Pb-TCMC-chOI-1 for targeted alpha-emitting radionuclide therapy. The results provide a rationale for further preclinical optimization of this therapeutic approach.

• Liukaityte, Rugile; Stenberg, Vilde Yuli; Kleinauskas, Andrius; Juzenas, Petras; Urbanucci, Alfonso & Juzeniene, Asta (2025). Combination of PSMA targeting alpha-emitting radioligand [212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models. Medical Oncology (MO). ISSN 1357-0560. 42(8). doi: 10.1007/s12032-025-02925-9. Full text in Research Archive Show summary

  The alpha-emitting radioligand [ 212 Pb]Pb-AB001, targeting prostate-specific membrane antigen (PSMA), is a promising therapy approach for prostate cancer. Bromodomain and extra-terminal (BET) protein inhibitors, such as AZD5153 and JQ1, disrupt oncogenic transcriptional programs by altering chromatin structure. This study evaluated whether BET inhibition enhances the efficacy of radioligand therapy. Cytotoxic effects of [ 212 Pb]Pb-AB001 alone and in combination with BET inhibitors were assessed in 2D monolayers and a 3D spheroid model of PSMA-positive C4-2 prostate cancer cells. Cell viability, cell cycle alterations, and DNA damage were assessed using viability assays and flow cytometry. Spheroid growth and viability were assessed by fluorescence microscopy. AZD5153 was more potent than JQ1 in reducing cell proliferation. [ 212 Pb]Pb-AB001 induced activity- and time-dependent cytotoxicity with a delayed apoptotic response. BET inhibitors induced G1 arrest, while [ 212 Pb]Pb-AB001 caused G2 arrest. Combination treatment reduced cell viability in an additive manner but did not further affect cell cycle distribution or increase apoptosis compared with [ 212 Pb]Pb-AB001 alone. γH2AX staining in 2D models showed an activity- and time-dependent increase in DNA damage at 1, 3 and 6 days post-treatment with [ 212 Pb]Pb-AB001. BET inhibitors alone induced minimal γH2AX, and combination treatments did not enhance DNA damage beyond [ 212 Pb]Pb-AB001 alone. In 3D spheroids, combination treatment led to synergistic growth suppression. In conclusion, these findings indicate that therapeutic inhibition of BET bromodomain in combination with the alpha-emitting radioligand [ 212 Pb]Pb-AB001 could significantly enhance tumour control and should be further evaluated in metastatic prostate cancer models.

• Tornes, Anna Julie Kjøl; Stenberg, Vilde Yuli; Liukaityte, Rugile; Llamazares, Ada Repetto; Qian, Peng & Wangen-Riise, Rina [Show all 10 contributors for this article] (2025). Optimizing [212Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts. Journal of Nuclear Medicine. ISSN 0161-5505. 66(12), p. 1956–1963. doi: 10.2967/jnumed.125.270444. Full text in Research Archive
• Song, Linlin; Kostas, Michal Janusz; Lærdahl, Jon Kristen; Skálová, Marie; Janská, Tereza & Juzeniene, Asta [Show all 14 contributors for this article] (2025). Preparation and Characterization of an Engineered FGF1 Conjugated to 161 Tb for Targeting of FGFRs. ACS Omega. 10(6), p. 5730–5743. doi: 10.1021/acsomega.4c09179. Full text in Research Archive Show summary

  The fibroblast growth factor receptor family members, FGFR1-4, are frequently overexpressed in various solid tumors, including breast cancer and sarcomas. This overexpression highlights the potential of the family of FGFRs as promising targets for cancer therapy. However, conventional FGFR kinase inhibitors often encounter challenges such as limited efficacy or drug resistance. In this study, we pursue an alternative strategy by designing a conjugate of the FGFR ligand FGF1 with the radioisotope 161Tb, for targeted therapy in FGFR-overexpressing cancer cells. FGF1 was engineered (eFGF1) to incorporate a single cysteine at the C terminus for site-specific labeling with a DOTA chelator. eFGF1-DOTA was mixed with the radioisotope 161Tb under mild conditions, resulting in a labeling efficiency above 90%. The nonradioactive ligands were characterized by mass spectrometry, while radioligands were characterized by thin-layer chromatography. The targeting function of the radioligands was assessed through confocal microscopy, flow cytometry, and Western blot analysis, focusing on binding to cancer cells and the activation of downstream signaling pathways related to FGFR. When compared to MCF-7 and RD cell lines with low FGFR expression, eFGF1-DOTA-Tb[161Tb] radioligands demonstrated significantly higher accumulation in FGFR-overexpressing cell lines (MCF-7 FGFR1 and RMS559), leading to enhanced cytotoxicity. Besides radionuclides, eFGF1 can also deliver doxorubicin (DOX) into cancer cells. Considering these characteristics, eFGF1-DOTA-Tb[161Tb] and eFGF1-DOX emerge as promising candidates for FGFR-targeted cancer therapy, and further evaluation in vivo is warranted.

• Tornes, Anna Julie Kjøl; Kvassheim, Monika; Ma, Li-Wei; Wiig, Elisabeth; Hillestad, Tiril & Rootwelt-Revheim, Mona-Elisabeth [Show all 9 contributors for this article] (2025). Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. ISSN 1619-7070. 52, p. 4847–4859. doi: 10.1007/s00259-025-07330-y. Full text in Research Archive Show summary

  Background Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [177Lu]Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA) and may be less efficient against micrometastatic disease. The alpha-emitting radioligand [212Pb]Pb-AB001 could offer enhanced treatment by delivering high energy over a short range. This study compared the efficacy of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer. Methods Binding and internalisation of radioligands were evaluated in PC-3 PIP-luc cells. A mouse model was established by intracardiac injection of these cells. Treatments with 0.24‒1.0 MBq [212Pb]Pb-AB001 or 22‒66 MBq [177Lu]Lu-PSMA-617 were initiated 7 d post-cell inoculation. Metastatic burden was measured using bioluminescence imaging, and PSMA-targeted uptake was determined with [18F]F-PSMA-1007 µPET/µCT. Gamma-autoradiography evaluated [212Pb]Pb-AB001 distribution, and bone metastases were identified by radiography. Results Both radioligands displayed comparable in vitro binding. In vivo studies revealed metastatic formation in clinically relevant organs. µPET/µCT demonstrated increased [18F]F-PSMA-1007 uptake in metastases, matching the bioluminescence imaging results. Focal [212Pb]Pb-AB001 distribution in the metastatic xenograft indicated heterogeneously distributed micrometastases in the organs. A median survival up to 47 d was achieved with [212Pb]Pb-AB001, compared to 25 d for controls and 27 d for [177Lu]Lu-PSMA-617. An activity-dependent reduction in bone metastases was observed for [177Lu]Lu-PSMA-617, while no bone lesions were detected in [212Pb]Pb-AB001-treated mice. Conclusion [212Pb]Pb-AB001 showed significant efficacy against micrometastases and advantages over [177Lu]Lu-PSMA-617 in preventing or treating early bone metastases for the investigated injected activities. This implies clinical potential for treating mCRPC, including patients at risk of early metastatic disease, but further studies including dosimetry and toxicity analyses are required with regards to activity levels.

• Lindland, Kim; Malenge, Marion Masitsa; Li, Ruth Gong; Wouters, Roxanne; Bønsdorff, Tina Bjørnlund & Juzeniene, Asta [Show all 7 contributors for this article] (2024). Antigen targeting and anti-tumor activity of a novel anti-CD146 ²¹²Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma. Scientific Reports. 14. doi: 10.1038/s41598-024-76778-z. Full text in Research Archive Show summary

  Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of a radioimmunoconjugate to locally target mesothelioma cancer cells has been proposed as a treatment. CD146, upregulated in mesothelioma but not in healthy tissues, is a promising therapeutic target. This study characterized CD146 expression and binding/internalization kinetics of the CD146-targeting antibody OI-3 coupled with 212Pb (212Pb-TCMC-OI-3) in human mesothelioma cells. Flow cytometry showed that both chimeric (chOI-3) and murine (mOI-3) antibodies rapidly bound and internalized within 1–6 h in MSTO-211H cells. 212Pb-TCMC-chOI-3 exhibited 3.1- to 13.7-fold and 3.1- to 8.5-fold increased internalized 212Pb and 212Bi atoms per cell at 2 and 24 h, respectively, compared to isotype control, underscoring enhanced internalization efficiency. Intraperitoneal administration of 212Pb-TCMC-mOI-3 to mice with intraperitoneal MSTO-211H xenografts improved median survival by a ratio of 1.3 compared to non-binding 212Pb-TCMC-mIgG1. The ability of 212Pb-TCMC-mOI-3 to target and inhibit the growth of intraperitoneal mesothelioma xenografts supports targeted radionuclide therapy’s efficacy for metastatic peritoneal mesothelioma. This study highlights the potential of localized CD146-targeted radioimmunotherapy for malignant mesothelioma, offering a new avenue for improving patient outcomes.

• Sioud, Mouldi; Juzeniene, Asta & Sæbøe-Larssen, Stein (2024). Exploring the Impact of mRNA Modifications on Translation Efficiency and Immune Tolerance to Self-Antigens. Vaccines. 12(6). doi: 10.3390/vaccines12060624. Full text in Research Archive
• Juzenienne, Asta; Stenberg, Vilde Yuli; Bruland, Øyvind; Rootwelt-Revheim, Mona Elisabeth & Larsen, Roy Hartvig (2023). Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach. Frontiers in Medicine. 9:1051825, p. 1–12. doi: 10.3389/fmed.2022.1051825. Full text in Research Archive Show summary

  Metastases are the primary cause of death among cancer patients and efficacious new treatments are sorely needed. Targeted alpha-emitting radiopharmaceuticals that are highly cytotoxic may fulfill this critical need. The focus of this paper is to describe and explore a novel technology that may improve the therapeutic effect of targeted alpha therapy by combining two radionuclides from the same decay chain in the same solution. We hypothesize that the dual targeting solution containing bone-seeking 224 Ra and cell-directed complexes of progeny 212 Pb is a promising approach to treat metastatic cancers with bone and soft tissue lesions as well as skeletal metastases of mixed lytic/osteoblastic nature. A novel liquid 224 Ra/ 212 Pb-generator for rapid preparation of a dual targeting solution is described. Cancer cell targeting monoclonal antibodies, their fragments, synthetic proteins or peptides can all be radiolabeled with 212 Pb in the 224 Ra-solution in transient equilibrium with daughter nuclides. Thus, 224 Ra targets stromal elements in sclerotic bone metastases and 212 Pb-chelated-conjugate targets tumor cells of metastatic prostate cancer or osteosarcoma. The dual targeting solution may also be explored to treat metastatic breast cancer or multiple myeloma after manipulation of bone metastases to a more osteoblastic phenotype by the use of bisphosphonates, denosumab, bortezomib or hormone therapy prior to treatment. This may improve targeting of bone-seeking 224 Ra and render an augmented radiation dose deposited within metastases. Our preliminary preclinical studies provide conceptual evidence that the dual 224 Ra-solution with bone or tumor-targeted delivery of 212 Pb has potential to inhibit cancer metastases without significant toxicity. In some settings, the use of a booster dose of purified 212 Pb-conjugate alone could be required to elevate the effect of this tumor cell directed component, if needed, e.g., in a fractionated treatment regimen, where the dual targeting solution will act as maintenance treatment.

• Mensali, Nadia; Köksal, Hakan; Joaquina, Sandy; Vernhoff, Håkan Patrik; Casey, Nicholas Paul & Romecin, Paola [Show all 27 contributors for this article] (2023). ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma. Nature Communications. 14. doi: 10.1038/s41467-023-39097-x. Full text in Research Archive Show summary

  Abstract Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. Here we show that chimeric antigen receptor (CAR) T cells could successfully target an isoform of alkaline phosphatase, ALPL-1, which is highly and specifically expressed in primary and metastatic OS. The target recognition element of the second-generation CAR construct is based on two antibodies, previously shown to react against OS. T cells transduced with these CAR constructs mediate efficient and effective cytotoxicity against ALPL-positive cells in in vitro settings and in state-of-the-art in vivo orthotopic models of primary and metastatic OS, without unexpected toxicities against hematopoietic stem cells or healthy tissues. In summary, CAR-T cells targeting ALPL-1 show efficiency and specificity in treating OS in preclinical models, paving the path for clinical translation.

• Kvassheim, Monika; Tornes, Anna Julie Kjøl; Juzenienne, Asta; Stokke, Caroline & Rootwelt-Revheim, Mona Elisabeth (2023). Imaging of 212Pb in mice with a clinical SPECT/CT. EJNMMI Physics. ISSN 2197-7364. 10(1), p. 1–11. doi: 10.1186/s40658-023-00571-6. Full text in Research Archive
• Stenberg, Vilde Yuli; Tornes, Anna Julie Kjøl; Nilsen, Hogne Røed; Rootwelt-Revheim, Mona Elisabeth; Bruland, Øyvind & Larsen, Roy Hartvig [Show all 7 contributors for this article] (2022). Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001. Cancers. 14(11). doi: 10.3390/cancers14112784. Full text in Research Archive Show summary

  This study aimed to determine the influence of cellular PSMA expression, radioligand binding and internalization, and repeated administrations on the therapeutic effects of the PSMA-targeting radioligand 212Pb-NG001. Cellular binding and internalization, cytotoxicity, biodistribution, and the therapeutic efficacy of 212Pb-NG001 were investigated in two human prostate cancer cell lines with different PSMA levels: C4-2 (PSMA+) and PC-3 PIP (PSMA+++). Despite 10-fold higher PSMA expression on PC-3 PIP cells, cytotoxicity and therapeutic efficacy of the radioligand was only 1.8-fold better than for the C4-2 model, possibly explained by lower cellular internalization and less blood-rich stroma in PC-3 PIP xenografts. Mice bearing subcutaneous PC-3 PIP xenografts were treated with 0.2, 0.4, and 0.8 MBq of 212Pb-NG001 that resulted in therapeutic indexes of 2.7, 3.0, and 3.5, respectively. A significant increase in treatment response was observed in mice that received repeated injections compared to the corresponding single dose (therapeutic indexes of 3.6 for 2 × 0.2 MBq and 4.4 for 2 × 0.4 MBq). The results indicate that 212Pb-NG001 can induce therapeutic effects at clinically transferrable doses, both in the C4-2 model that resembles solid tumors and micrometastases with natural PSMA expression and in the PC-3 PIP model that mimics poorly vascularized metastases.

• Ghiasvand, Reza; Berge, Leon Alexander Mclaren; Kulle, Bettina; Stenehjem, Jo Steinson; Heir, Trond & Karlstad, Øystein [Show all 11 contributors for this article] (2022). Use of antihypertensive drugs and risk of cutaneous melanoma: A nationwide nested case-control study. International Journal of Epidemiology. ISSN 0300-5771. 52(3), p. 887–898. doi: 10.1093/ije/dyac223. Full text in Research Archive Show summary

  Abstract Background Most antihypertensives can induce dermal photosensitivity, which may increase melanoma risk. However, corroborating evidence is limited. We examined the associations between use of antihypertensives and melanoma risk. Methods A nationwide nested case-control study was conducted using data from the Cancer Registry of Norway, the National Registry and the Norwegian Prescription Database in 2004–15. Ten controls were randomly selected for each melanoma case, matched on sex and birth year. The study included 12 048 cases and 117 895 controls. We estimated rate ratios (RRs) with 95% confidence intervals (CIs). All analyses were adjusted for ambient ultraviolet radiation (UVR). We additionally performed active comparator analyses, and sensitivity analyses by only including new users, distinguishing between exclusive and mixed users, allowing for different latency periods, and subgroup analyses by melanoma subtype and clinical stage. Results Compared with non-use, we observed a slightly increased melanoma risk in users of diuretics (RR 1.08, CI 1.01–1.15), calcium-channel blockers (RR 1.10, CI 1.04–1.18) and drugs affecting the renin-angiotensin system (RR 1.10, CI 1.04–1.16), but not for beta blockers (RR 0.97, CI 0.92–1.03). We found no heterogeneity of associations by melanoma subtype or clinical stage and no dose-response relationship between the cumulative defined daily doses (DDDs) and melanoma. No interaction was found between cumulative DDDs and ambient UVR. Conclusions Weak associations, with lack of a dose-response relationship and lack of interactions with ambient UVR, in the DDD analysis in this nationwide study do not support a causal relationship between antihypertensives and melanoma risk.

• Tornes, Anna Julie Kjøl; Stenberg, Vilde Yuli; Bruland, Øyvind; Rootwelt-Revheim, Mona Elisabeth; Larsen, Roy H & Juzenienne, Asta (2022). Targeted alpha therapy with the 224Ra/212Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma. Frontiers in Medicine. 9. doi: 10.3389/fmed.2022.1058863. Full text in Research Archive Show summary

  Osteosarcoma patients with overt metastases at primary diagnosis have a 5-year survival rate of less than 20%. TP-3 is a murine IgG2b monoclonal antibody with high affinity for an epitope residing on the p80 osteosarcoma cell surface membrane antigen. The tumor-associated antigen p80 is overexpressed in osteosarcomas, and has very low normal tissue expression. We propose a novel dual alpha targeting solution containing two radionuclides from the same decay chain, including the bone-seeking 224 Ra, and cancer cell-surface seeking 212 Pb-TCMC-TP-3 for the treatment of osteoblastic bone cancers, circulating cancer cells and micrometastases. In this in vitro study, the cytotoxic effects of 212 Pb-TCMC-TP-3 (single alpha solution) and 224 Ra/ 212 Pb-TCMC-TP-3 (dual alpha solution) were investigated in a multicellular spheroid model mimicking micrometastatic disease in osteosarcoma. OHS spheroids with diameters of 253 ± 98 μm treated with 4.5, 2.7, and 3.3 kBq/ml of 212 Pb-TCMC-TP-3 for 1, 4, and 24 h, respectively, were disintegrated within 3 weeks. The 212 Pb-TCMC-TP-3 induced a 7-fold delay in spheroid doubling time compared to a 28-times higher dose with the non-specific 212 Pb-TCMC-rituximab. The 224 Ra/ 212 Pb-TCMC-TP-3 completely disintegrated spheroids with diameters of 218–476 μm within 3 and 2 weeks after 4 and 24 h incubation with 5 kBq/ml, respectively. Treatment with 1 kBq/ml of 224 Ra/ 212 Pb-TCMC-TP-3 for 24 h caused an 11.4-fold reduction in spheroid viability compared with unconjugated 224 Ra/ 212 Pb. The single and dual alpha solutions with TP-3 showed cytotoxicity in spheroids of clinically relevant size, which warrant further testing of the dual alpha solution using in vivo osteosarcoma models.

• Juzeniene, Asta; Stenberg, Vilde Yuli; Bruland, Øyvind & Larsen, Roy Hartvig (2021). Preclinical and clinical status of psma-targeted alpha therapy for metastatic castration-resistant prostate cancer. Cancers. 13:779(4), p. 1–25. doi: 10.3390/cancers13040779. Full text in Research Archive Show summary

  Bone, lymph node, and visceral metastases are frequent in castrate-resistant prostate cancer patients. Since such patients have only a few months’ survival benefit from standard therapies, there is an urgent need for new personalized therapies. The prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a molecular target for imaging diagnostics and targeted radionuclide therapy (theragnostics). PSMA-targeted α therapies (PSMA-TAT) may deliver potent and local radiation more selectively to cancer cells than PSMA-targeted β− therapies. In this review, we summarize both the recent preclinical and clinical advances made in the development of PSMA-TAT, as well as the availability of therapeutic α-emitting radionuclides, the development of small molecules and antibodies targeting PSMA. Lastly, we discuss the potentials, limitations, and future perspectives of PSMA-TAT.

• Köksal, Hakan; Dillard, Pierre; Juzeniene, Asta; Kvalheim, Gunnar; Smeland, Erlend B. & Myklebust, June Helen [Show all 8 contributors for this article] (2021). Combinatorial CAR design improves target restriction. Journal of Biological Chemistry. ISSN 0021-9258. 296:100116, p. 1–13. doi: 10.1074/jbc.RA120.016234. Full text in Research Archive Show summary

  CAR T cells targeting the B lymphocyte antigen CD19 have led to remarkable clinical results in B cell leukemia and lymphoma but eliminate all B lineage cells, leading to increased susceptibility to severe infections. As malignant B cells will express either immunoglobulin (Ig) light chain κ or λ, we designed a second-generation CAR targeting Igκ, IGK CAR. This construct demonstrated high target specificity but displayed reduced efficacy in the presence of serum IgG. Since CD19 CAR is insensitive to serum IgG, we designed various combinatorial CAR constructs in order to maintain the CD19 CAR T cell efficacy, but with IGK CAR target selectivity. The Kz-19BB design, combining CD19 CAR containing a 4-1BB costimulatory domain with an IGK CAR containing a CD3zeta stimulatory domain, maintained the target specificity of IgK CAR and was resistant to the presence of soluble IgG. Our results demonstrate that a combinatorial CAR approach can improve target selectivity and efficacy.

• Stenberg, Vilde Yuli; Larsen, Roy H.; Ma, Li-Wei; Qian, Peng; Juzenas, Petras & Bruland, Øyvind [Show all 7 contributors for this article] (2021). Evaluation of the psma-binding ligand²¹²pb-ng001 in multicellular tumour spheroid and mouse models of prostate cancer. International Journal of Molecular Sciences. ISSN 1661-6596. 22(9). doi: 10.3390/ijms22094815. Full text in Research Archive
• Li, Ruth Gong; Lindland, Kim; Tonstad, Sandra Karen; Bønsdorff, Tina Bjørnlund; Juzeniene, Asta & Westrøm, Sara [Show all 7 contributors for this article] (2021). Improved formulation of ²²⁴Ra-labeled calcium carbonate microparticles by surface layer encapsulation and addition of EDTMP. Pharmaceutics. 13(5), p. 1–17. doi: 10.3390/pharmaceutics13050634. Full text in Research Archive
• Li, Ruth Gong; Napoli, Elisa; Jorstad, Ida Sofie; Bønsdorff, Tina Bjørnlund; Juzeniene, Asta & Bruland, Øyvind Sverre [Show all 8 contributors for this article] (2021). Calcium carbonate microparticles as carriers of 224Ra: Impact of specific activity in mice with intraperitoneal ovarian cancer. Current Radiopharmaceuticals. ISSN 1874-4710. 14(2), p. 145–153. doi: 10.2174/1874471013666201201102056. Full text in Research Archive Show summary

  Background: Patients with advanced-stage ovarian cancer face a poor prognosis because of recurrent peritoneal cavity metastases following surgery and chemotherapy. Alpha-emitters may enable the efficient treatment of such disseminated diseases because of their short range and highly energetic radiation. Radium-224 is a candidate α-emitter due to its convenient 3.6-day half-life, with more than 90% of the decay energy originating from α-particles. However, its inherent skeletal accumulation must be overcome to facilitate intraperitoneal delivery of the radiation dose. Therefore, 224Ra-labeled CaCO3 microparticles have been developed. Objective: The antitumor effect of CaCO3 microparticles as a carrier for 224Ra was investigated, with an emphasis on the ratio of activity to mass dose of CaCO3, that is, specific activity. Methods: Nude athymic mice were inoculated intraperitoneally with human ovarian cancer cells (ES-2) and treated with a single intraperitoneal injection of 224Ra-labeled CaCO3 microparticles with varying combinations of mass and activity dose, or cationic 224Ra in solution. Survival and ascites volume at sacrifice were evaluated. Results: Significant therapeutic effect was achieved for all tested specific activities ranging from 0.4 to 4.6 kBq/mg. Although treatment with a mean activity dose of 1305 kBq/kg of cationic 224Ra prolonged the survival compared with the control, equivalent median survival could be achieved with 224Ra-labeled microparticles with a mean dose of only 420 kBq/kg. The best outcome was achieved with the highest specific activities (2.6 and 4.6 kBq/mg). Conclusion: Radium-224-labeled CaCO3 microparticles present a promising therapy against cancer dissemination in body cavities.

• Berge, Leon Alexander; Kulle, Bettina; Stenehjem, Jo S.; Heir, Trond; Furu, Kari & Juzeniene, Asta [Show all 11 contributors for this article] (2020). Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry-Based Case-Control Study. Clinical Epidemiology. 12, p. 193–202. doi: 10.2147/CLEP.S241249. Full text in Research Archive Show summary

  Purpose: Melanoma is the cancer with the most rapidly rising incidence rate in Norway. Although exposure to ultraviolet radiation (UVR) is the major environmental risk factor, other factors may also contribute. Antidepressants have cancer inhibiting and promoting side effects, and their prescription rates have increased in parallel with melanoma incidence. Thus, we aimed to prospectively examine the association between use of antidepressants and melanoma by using nation-wide data from the Cancer Registry of Norway, the National Registry, the Norwegian Prescription Database and the Medical Birth Registry of Norway. Patient and Methods: All cases aged 18– 85 with a primary cutaneous invasive melanoma diagnosed during 2007– 2015 (n=12,099) were matched to population controls 1:10 (n=118,467) by sex and year of birth using risk-set sampling. We obtained information on prescribed antidepressants and other potentially confounding drug use (2004– 2015). Conditional logistic regression was used to estimate adjusted rate ratios (RRs) and 95% confidence intervals (CIs) for the association between overall and class-specific use of antidepressants and incident melanoma. Results: Compared with ≤ 1 prescription, ≥ 8 prescriptions of antidepressants overall were negatively associated with melanoma (RR 0.81 CI 0.75– 0.87). Class-specific analyses showed decreased RRs for selective serotonin reuptake inhibitors (RR 0.82 CI 0.73– 0.93) and mixed antidepressants (RR 0.77 CI 0.69– 0.86). The negative association was found for both sexes, age ≥ 50 years, residential regions with medium and highest ambient UVR exposure, all histological subtypes, trunk, upper and lower limb sites and local disease. Conclusion: Use of antidepressants was associated with decreased risk of melanoma. There are at least two possible explanations for our results; cancer-inhibiting actions induced by the drug and less UVR exposure among the most frequent users of antidepressants.

• Stenberg, Vilde Yuli; Juzeniene, Asta; Chen, Qingqi; Yang, Xiaoming; Bruland, Øyvind & Larsen, Roy Hartvig (2020). Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212Pb]Pb-NG001 for prostate cancer. Journal of labelled compounds & radiopharmaceuticals. ISSN 0362-4803. 63(3), p. 129–143. doi: 10.1002/jlcr.3825. Full text in Research Archive Show summary

  Prostate‐specific membrane antigen (PSMA) is the most promising target for radioligand therapy of prostate cancer. The aim of this study was to prepare a small molecular ligand p‐SCN‐Bn‐TCMC‐PSMA (NG001) and compare it with the commonly used DOTA‐based PSMA‐617. The PSMA‐targeting ability of the 212Pb‐labelled ligands was evaluated using PSMA‐positive C4‐2 human prostate cancer cells. Lead‐212 is an in vivo generator of alpha particles by its daughter nuclides 212Bi and 212Po. NG001 was synthesized by conjugating the isothiocyanato group of p‐SCN‐Bn‐TCMC to the amino group of a glutamate‐urea‐based PSMA‐binding entity. Molecular size, chelator unit and chelator linking method are different in NG001 and PSMA‐617. Both ligands were efficiently labelled with 212Pb using a 224Ra/212Pb‐solution generator in transient equilibrium with progeny. Lead‐212‐labelled NG001 was purified with a yield of 85.9±4.7% and with 0.7±0.2% of 224Ra. Compared with [212Pb]Pb‐PSMA‐617, [212Pb]Pb‐NG001 displayed a similar binding and internalization in C4‐2 cells, with comparable tumour uptake in mice bearing C4‐2 tumours, but almost a 2.5‐fold lower kidney uptake. Due to the rapid normal tissue clearance and tumour cell internalization, any significant translocalization of 212Bi was not detected in mice. In conclusion, the obtained results warrant further preclinical studies to evaluate the therapeutic efficacy of [212Pb]Pb‐NG001.

• Stenberg, Vilde Yuli; Juzeniene, Asta; Bruland, Øyvind & Larsen, Roy H. (2020). In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells. Current Radiopharmaceuticals. ISSN 1874-4710. 13(2), p. 130–141. doi: 10.2174/1874471013666200511000532. Full text in Research Archive Show summary

  Background: New treatments combating bone and extraskeletal metastases are needed for patients with metastatic castration-resistant prostate cancer. The majority of metastases overexpress prostate-specific membrane antigen (PSMA), making it an ideal candidate for targeted radionuclide therapy. Objective: The aim of this study was to test a novel liquid 224Ra/212Pb-generator for the rapid preparation of a dual-alpha targeting solution. Here, PSMA-targeting ligands are labelled with 212Pb in the 224Ra-solution in transient equilibrium with daughter nuclides. Thus, natural bone-seeking 224Ra targeting sclerotic bone metastases and 212Pb-chelated PSMA ligands targeting PSMA-expressing tumour cells are obtained. Methods: Two PSMA-targeting ligands, the p-SCN-Bn-TCMC-PSMA ligand (NG001), specifically developed for chelating 212Pb, and the most clinically used DOTA-based PSMA-617 were labelled with 212Pb. Radiolabelling and targeting potential were investigated in situ, in vitro (PSMA-positive C4-2 human prostate cancer cells) and in vivo (athymic mice bearing C4-2 xenografts). Results: NG001 was rapidly labelled with 212Pb (radiochemical purity >94% at concentrations of ≥15 μg/ml) using the liquid 224Ra/212Pb-generator. The high radiochemical purity and stability of [212Pb]Pb-NG001 were demonstrated over 48 hours in the presence of ascorbic acid and albumin. Similar binding abilities of the 212Pb-labelled ligands were observed in C4-2 cells. The PSMA ligands displayed comparable tumour uptake after 2 hours, but NG001 showed a 3.5-fold lower kidney uptake than PSMA-617. Radium-224 was not chelated and, hence, showed high uptake in bones. Conclusion: A fast method for the labelling of PSMA ligands with 212Pb in the 224Ra/212Pb-solution was developed. Thus, further in vivo studies with dual tumour targeting by alpha-particles are warranted.

• Napoli, Elisa; Stenberg, Vilde Yuli; Juzeniene, Asta; Hjellum, Gro E.; Bruland, Øyvind & Larsen, Roy H. (2020). Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples. Applied Radiation and Isotopes. ISSN 0969-8043. 166:109362, p. 1–9. doi: 10.1016/j.apradiso.2020.109362. Full text in Research Archive Show summary

  Lead-212 is a promising radionuclide for cancer therapy, but no primary 212Pb activity standardization has been published. A need therefore exists for accurate estimation of injected doses of 212Pb activity in equilibrium with progeny, when it comes to preclinical and clinical trials. In this study, 212Pb activity was determined using a high purity germanium (HPGe) detector, which allowed the determination of geometry-specific calibration factors for commercially available reentrant ionization chambers (ICs) and sodium iodide (NaI) detectors.

• Grigalavicius, Mantas; Mastrangelopoulou, Maria; Arous, Delmon; Juzeniene, Asta; Ménard, Mathilde & Skarpen, Ellen [Show all 8 contributors for this article] (2020). Photodynamic efficacy of cercosporin in 3D tumor cell CCultures. Photochemistry and Photobiology. ISSN 0031-8655. 96(3), p. 699–707. doi: 10.1111/php.13257. Full text in Research Archive Show summary

  In the present work, we study the photodynamic action of cercosporin (cerco), a naturally occurring photosensitizer, on human cancer multicellular spheroids. U87 spheroids exhibit double the uptake of cerco than T47D and T98G spheroids as shown by flow cytometry on the single cell level. Moreover, cerco is efficiently internalized by cells throughout the spheroid as shown by confocal microscopy, for all three cell lines. Despite their higher cerco uptake, U87 spheroids show the least vulnerability to cerco‐PDT, in contrast to the other two cell lines (T47D and T98G). While 300 μm diameter spheroids consistently shrink and become necrotic after cerco PDT, bigger spheroids (>500 μm) start to regrow following blue‐light PDT and exhibit high viability. Cerco‐PDT was found to be effective on bigger spheroids reaching 1mm in diameter especially under longer exposure to yellow light (~590 nm). In terms of metabolism, T47D and T98G undergo a complete bioenergetic collapse (respiration and glycolysis) as a result of cerco‐PDT. U87 spheroids also experienced a respiratory collapse following cerco‐PDT, but retained half their glycolytic activity.

• Berge, Leon Alexander; Kulle, Bettina; Stenehjem, Jo S.; Heir, Trond; Karlstad, Øystein & Juzeniene, Asta [Show all 11 contributors for this article] (2020). Use of immunomodulating drugs and risk of cutaneous melanoma: A nationwide nested case-control study. Clinical Epidemiology. 12, p. 1389–1401. doi: 10.2147/CLEP.S269446. Full text in Research Archive Show summary

  Purpose: Cutaneous melanoma is among the fastest growing malignancies in Norway and ultraviolet radiation (UVR) exposure is the primary environmental risk factor. Immunomodulating drugs can increase skin photosensitivity and suppress immune responses, and by such mechanisms influence melanoma risk. We, therefore, aimed to examine the associations between use of immunomodulating drugs and melanoma risk, at a nationwide population level. Patients and Methods: In the Cancer Registry of Norway, we identified all cases aged 18– 85 with a first primary cutaneous melanoma diagnosed in 2007– 2015 (n=12,106). These were matched to population controls from the Norwegian National Registry 1:10 (n=118,564), on sex and year of birth using risk set sampling. Information on prescribed drugs (2004– 2015) was obtained by linkage to the Norwegian Prescription Database (NorPD). Conditional logistic regression was used to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for associations between use of immunomodulating drugs (immunosuppressants and corticosteroids) and melanoma risk, adjusted for ambient UVR and other drug use. Results: Compared with ≤ 1 prescription, use of ≥ 8 prescriptions of immunosuppressants was associated with increased risk of melanoma (RR 1.50, 95% CI 1.27, 1.77). Similar associations were found for subgroups of immunosuppressants: drugs typically prescribed to organ transplant recipients (OTRs) (RR 2.02, 95% CI 1.35, 3.03) and methotrexate (RR 1.27, 95% CI 1.04, 1.55). Similar results were found for high levels of cumulative doses and across all histological subtypes. Use of corticosteroids was not associated with melanoma risk. Conclusion: We found a positive association between use of immunosuppressants and melanoma risk, with the highest risk seen for drugs prescribed to OTRs. Knowledge about this risk increase is important for physicians and users of these drugs, for intensified surveillance, awareness and cautious sun exposure.

• Berge, Leon Alexander; Kulle, Bettina; Stenehjem, Jo S.; Larsen, Inger Kristin; Furu, Kari & Juzeniene, Asta [Show all 11 contributors for this article] (2019). Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: A protocol for a prospective case-control study. BMJ Open. 9:e025246(2), p. 1–8. doi: 10.1136/bmjopen-2018-025246. Full text in Research Archive Show summary

  The incidence of cutaneous melanoma (hereafter melanoma) has increased dramatically among fair-skinned populations worldwide. In Norway, melanoma is the most rapidly growing type of cancer, with a 47% increase among women and 57% among men in 2000–2016. Intermittent ultraviolet exposure early in life and phenotypic characteristics like a fair complexion, freckles and nevi are established risk factors, yet the aetiology of melanoma is multifactorial. Certain prescription drugs may have carcinogenic side effects on the risk of melanoma. Some cardiovascular, antidepressant and immunosuppressive drugs can influence certain biological processes that modulate photosensitivity and immunoregulation. We aim to study whether these drugs are related to melanoma risk.Methods and analysisA population-based matched case–control study will be conducted using nation-wide registry data. Cases will consist of all first primary, histologically verified melanoma cases diagnosed between 2007 and 2015 identified in the Cancer Registry of Norway (14 000 cases). Ten melanoma-free controls per case (on date of case melanoma diagnosis) will be matched based on sex and year of birth from the National Registry of Norway. For the period 2004—2015, and by using the unique personal identification numbers assigned to all Norwegian citizens, the case–control data set will be linked to the Norwegian Prescription Database for information on drugs dispensed prior to the melanoma diagnosis, and to the Medical Birth Registry of Norway for data regarding the number of child births. Conditional logistic regression will be used to estimate associations between drug use and melanoma risk, taking potential confounding factors into account.Ethics and disseminationThe project is approved by the Regional Committee for Medical Research Ethics in Norway and by the Norwegian Data Protection Authority. The study is funded by the Southeastern Norway Regional Health Authority. Results will be published in peer-reviewed journals and disseminated further through scientific conferences, news media and relevant patient interest groups.

• Juzeniene, Asta; Bernoulli, Jenni; Suominen, Mari; Halleen, Jussi & Larsen, Roy Hartvig (2018). Antitumor activity of novel bone-seeking, α-emitting 224Ra-solution in a Breast Cancer Skeletal Metastases Model. Anticancer Research. ISSN 0250-7005. 38(4), p. 1947–1955. doi: 10.21873/anticanres.12432. Full text in Research Archive
• Grigalavicius, Mantas; Juraleviciute, Marina; Kwitniewski, Mateusz & Juzeniene, Asta (2017). The influence of photodynamic therapy with 5-aminolevulinic acid on senescent skin cancer cells. Photodiagnosis and Photodynamic Therapy. ISSN 1572-1000. 17, p. 29–34. doi: 10.1016/j.pdpdt.2016.10.008. Full text in Research Archive
• Gaware, Vivek S.; Håkerud, Monika; Juzeniene, Asta; Høgset, Anders; Berg, Kristian & Másson, Már (2017). Endosome Targeting meso-Tetraphenylchlorin-Chitosan Nanoconjugates for Photochemical Internalization. Biomacromolecules. ISSN 1525-7797. 18(4), p. 1108–1126. doi: 10.1021/acs.biomac.6b01670. Full text in Research Archive
• Pudroma, Xiao; Duoji, Gongsang; Grigalavicius, Mantas; Jie, Duan & Juzeniene, Asta (2017). Molecular mechanisms of UVA-induced melanoma. Journal of Environmental Pathology And Toxicology. ISSN 0731-8898. 36(3), p. 217–228. doi: 10.1615/JEnvironPatholToxicolOncol.2017020213. Full text in Research Archive
• Juzeniene, Asta; Grigalavicius, Mantas; Ma, Li-Wei & Juraleviciute, Marina (2016). Folic acid and its photoproducts, 6-formylpterin and pterin-6-carboxylic acid, as generators of reactive oxygen species in skin cells during UVA exposure. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 155, p. 116–121. doi: 10.1016/j.jphotobiol.2016.01.001. Full text in Research Archive
• Juzeniene, Asta; Grigalavicius, Mantas; Juraleviciute, Marina & Grant, William B. (2016). Phototherapy and vitamin D. Clinics in Dermatology. ISSN 0738-081X. 34(5), p. 548–555. doi: 10.1016/j.clindermatol.2016.05.004. Full text in Research Archive
• Grigalavicius, Mantas; Iani, Vladimir & Juzeniene, Asta (2016). Layer thickness of spf 30 sunscreen and formation of pre-Vitamin D. Anticancer Research. ISSN 0250-7005. 36(3), p. 1409–1416. Full text in Research Archive
• Grant, William B.; Karras, Spyridon N.; Bischoff-Ferrari, Heike A; Annweiler, Cédric; Boucher, Barbara J. & Juzeniene, Asta [Show all 8 contributors for this article] (2016). Do studies reporting ‘U’-shaped serum 25- hydroxyvitamin D–health outcome relationships reflect adverse effects? Dermato-Endocrinology. ISSN 1938-1972. 8(1). doi: 10.1080/19381980.2016.1187349. Full text in Research Archive
• Moan, Johan Emilian; Juzeniene, Asta & Grigalavicius, Mantas (2016). Variasjon av solstrålingen med tid og breddegrad – betydning for D-vitaminproduksjon og udkreftfare. Bestpractice Onkologi/Hematologi. ISSN 2245-0440. Full text in Research Archive
• Grigalavicius, Mantas; Moan, Johan Emilian; Dahlback, Arne & Juzeniene, Asta (2016). Daily, seasonal, and latitudinal variations in solar ultraviolet A and B radiation in relation to vitamin D production and risk for skin cancer. International Journal of Dermatology. ISSN 0011-9059. 55(1), p. e23–e28. doi: 10.1111/ijd.13065. Full text in Research Archive
• Moan, Johan Emilian; Juzeniene, Asta & Grigalavicius, Mantas (2016). Fotodynamisk behandling gjennom 100 år. Bestpractice Onkologi/Hematologi. ISSN 2245-0440. Full text in Research Archive
• Moan, Johan Emilian; Grigalavicius, Mantas; Baturaite, Zivile; Dahlback, Arne & Juzeniene, Asta (2015). The relationship between UV exposure and incidence of skin cancer. Photodermatology, Photoimmunology & Photomedicine. ISSN 0905-4383. 31(1), p. 26–35. doi: 10.1111/phpp.12139. Full text in Research Archive
• Coelho, Silvia Castro; Pereira, Maria Carmo; Juzeniene, Asta; Juzenas, Petras & Coelho, Manuel A.N. (2015). Supramolecular nanoscale assemblies for cancer diagnosis and therapy. Journal of Controlled Release. ISSN 0168-3659. 213, p. 152–167. doi: 10.1016/j.jconrel.2015.06.034. Full text in Research Archive
• Juzeniene, Asta; Porojnicu, Alina Carmen; Baturaite, Zivile; Lagunova, Zoya; Aksnes, Lage & Bruland, Øyvind [Show all 7 contributors for this article] (2015). Vitamin D levels and dietary intake among patients with benign soft tissue tumors and sarcomas. Anticancer Research. ISSN 0250-7005. 35(2), p. 1171–1180. Full text in Research Archive
• Grigalavicius, Mantas; Moan, Johan Emilian; Dahlback, Arne & Juzeniene, Asta (2015). Vitamin D and ultraviolet phototherapy in Caucasians. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 147, p. 69–74. doi: 10.1016/j.jphotobiol.2015.03.009. Full text in Research Archive
• Juzeniene, Asta; Baturaite, Zivile; Lagunova, Zoya; Grigalavicius, Mantas; Porojnicu, Alina Carmen & Bruland, Øyvind [Show all 7 contributors for this article] (2015). Influence of multiple UV exposures on serum cobalamin and vitamin D levels in healthy females. Scandinavian Journal of Public Health. ISSN 1403-4948. 43(3), p. 324–330. doi: 10.1177/1403494815572206. Full text in Research Archive
• Juzeniene, Asta; Grigalavicius, Mantas; Baturaite, Zivile & Moan, Johan Emilian (2014). Minimal and maximal incidence rates of skin cancer in Caucasians estimated by use of sigmoidal UV dose-incidence curves. International Journal of Hygiene and Environmental Health. ISSN 1438-4639. 217(8), p. 839–844. doi: 10.1016/j.ijheh.2014.06.002. Full text in Research Archive
• Juzeniene, Asta; Tran, Thi Thu Tam; Iani, Vladimir & Moan, Johan Emilian (2013). The action spectrum for folic acid photodegradation in aqueous solutions. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 126, p. 11–16. doi: 10.1016/j.jphotobiol.2013.05.011. Full text in Research Archive
• Juzeniene, Asta & Baturaite, Zivile (2013). Photodegradation of cobalamins in aqueous solutions and in human blood. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 122, p. 7–14. doi: 10.1016/j.jphotobiol.2013.03.001. Full text in Research Archive
• Moan, Johan Emilian; Baturaite, Zivile; Grigalavicius, Mantas & Juzeniene, Asta (2013). Cutaneous malignant melanoma incidence rates in Norway. Scandinavian Journal of Public Health. ISSN 1403-4948. 41(4), p. 336–339. doi: 10.1177/1403494813479216. Full text in Research Archive
• Moan, Johan Emilian; Grigalavicius, Mantas; Baturaite, Zivile; Juzenienne, Asta & Dahlback, Arne (2013). North-South gradients of melanomas and non-melanomas: A role of vitamin D? Dermato-Endocrinology. ISSN 1938-1972. 5(1), p. 186–191. doi: 10.4161/derm.23791. Full text in Research Archive
• Juzeniene, Asta; Iani, Vladimir & Moan, Johan Emilian (2013). Clearance mechanism of protoporphyrin IX from mouse skin after application of 5-aminolevulinic acid. Photodiagnosis and Photodynamic Therapy. ISSN 1572-1000. 10(4), p. 538–545. doi: 10.1016/j.pdpdt.2013.05.008. Full text in Research Archive
• Orlova, Tetiana; Moan, Johan Emilian; Lagunova, Zoya; Aksnes, Lage; Terenetskaya, Irina & Juzeniene, Asta (2013). Increase in serum 25-hydroxyvitamin-D-3 in humans after sunbed exposures compared to previtamin D-3 synthesis in vitro. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 122, p. 32–36. doi: 10.1016/j.jphotobiol.2013.03.006. Full text in Research Archive
• Grigalavicius, Mantas; Juzenienne, Asta; Baturaite, Zivile; Dahlback, Arne & Moan, Johan Emilian (2013). Biologically efficient solar radiation: Vitamin D production and induction of cutaneous malignant melanoma. Dermato-Endocrinology. ISSN 1938-1972. 5(1), p. 150–158. doi: 10.4161/derm.22941. Full text in Research Archive
• Moan, Johan Emilian; Baturaite, Zivile; Juzeniene, Asta & Porojnicu, Alina Carmen (2012). Vitamin D, sun, sunbeds and health. Public Health Nutrition (PHN). ISSN 1368-9800. 15(4), p. 711–715. doi: 10.1017/S1368980011002801. Full text in Research Archive
• Juzeniene, Asta & Moan, Johan Emilian (2012). Beneficial effects of UV radiation other than via vitamin D production. Dermato-Endocrinology. ISSN 1938-1972. 4(2), p. 109–117. doi: 10.4161/derm.20013. Full text in Research Archive
• Juzeniene, Asta; Micu, Emanuela; Porojnicu, Alina Carmen & Moan, Johan Emilian (2012). Malignant melanomas on head/neck and foot: differences in time and latitudinal trends in Norway. Journal of the European Academy of Dermatology and Venereology. ISSN 0926-9959. 26(7), p. 821–827. doi: 10.1111/j.1468-3083.2011.04162.x. Full text in Research Archive
• Moan, Johan Emilian; Nielsen, Kristian Pagh & Juzeniene, Asta (2012). Immediate pigment darkening: its evolutionary roles may include protection against folate photosensitization. The FASEB Journal. ISSN 0892-6638. 26(3), p. 971–975. doi: 10.1096/fj.11-195859. Full text in Research Archive
• Uzdensky, Anatoly; Kristiansen, Bjørn Evert; Moan, Johan Emilian & Juzeniene, Asta (2012). Dynamics of signaling, cytoskeleton and cell cycle regulation proteins in glioblastoma cells after sub-lethal photodynamic treatment: Antibody microarray study. Biochimica et Biophysica Acta - General Subjects. ISSN 0304-4165. 1820(7), p. 795–803. doi: 10.1016/j.bbagen.2012.03.008. Full text in Research Archive
• Moan, Johan Emilian; Baturaite, Zivile; Porojnicu, Alina Carmen; Dahlback, Arne & Juzeniene, Asta (2012). UVA, UVB and incidence of cutaneous malignant melanoma in Norway and Sweden. Photochemical and Photobiological Sciences. ISSN 1474-905X. 11(1), p. 191–198. doi: 10.1039/c1pp05215b. Full text in Research Archive
• Micu, Emanuela; Baturaite, Zivile; Juzeniene, Asta; Bruland, Øyvind & Moan, Johan Emilian (2012). Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients. Melanoma research. ISSN 0960-8931. 22(6), p. 460–465. doi: 10.1097/CMR.0b013e3283599cc3. Full text in Research Archive
• Mikolajewska, Patrycja Maria; Rømoen, Ola Taarud; Martinsen, Ørjan Grøttem; Iani, Vladimir; Moan, Johan Emilian & Grimnes, Sverre [Show all 7 contributors for this article] (2011). Bioimpedance for pain monitoring during cutaneous photodynamic therapy: Preliminary study. Photodiagnosis and Photodynamic Therapy. ISSN 1572-1000. 8(4), p. 307–313. doi: 10.1016/j.pdpdt.2011.06.001. Full text in Research Archive
• Pudroma, Xiao; Juzeniene, Asta; Ma, Li Wei; Iani, Vladimir & Moan, Johan Emilian (2011). Fluorescence Photobleaching of ALA and ALA-Heptyl Ester Induced Protoporphyrin IX During Photodynamic Therapy of Normal Hairless Mouse Skin: A Comparison of Two Light Sources and Different Illumination Schemes. Journal of Environmental Pathology And Toxicology. ISSN 0731-8898. 30(3), p. 235–240. doi: 10.1615/jenvironpatholtoxicoloncol.v30.i3.60. Full text in Research Archive Show summary

  This study investigated photobleaching of protoporphyrin DC (PpIX) induced by 5-aminolevulinic acid (ALA) and ALA-heptyl ester during superficial photodynamic therapy (PDT) in normal skin of the female BALB/c-nu/nu athymic mouse. We examined the effects of two light sources (laser and broadband lamp) and two different illumination schemes (fractionated light and continuous irradiation) on the kinetics of photobleaching. Our results show that light exposure (0-30 minutes, 10 mW/cm(2)) of wavelengths of approximately 420 nm (blue light) and 635 nm (red light) induced time-dependent PpIX photobleaching for mouse skin of 2% ALA and ALA-heptyl ester. Blue light (10 mW/cm(2)) caused more rapid PpIX photobleaching than did red light (100 mW/cm(2)), which is attributed to stronger absorption at 407 nm than at 632 nm for PpIX. In the case of light fractionation, fractionated light induced faster photobleaching compared with continuous light exposure after topical application of 2% ALA and ALA-heptyl ester in vivo. These have been suggested to allow reoxygenation of the irradiated tissue, with a consequent enhancement of singlet oxygen production in the second and subsequent fractions.

• Micu, Emanuela; Juzeniene, Asta & Moan, Johan Emilian (2011). Comparison of the time and latitude trends of melanoma incidence in anorectal region and perianal skin with those of cutaneous malignant melanoma in Norway. Journal of the European Academy of Dermatology and Venereology. ISSN 0926-9959. 25(12), p. 1444–1449. doi: 10.1111/j.1468-3083.2011.04023.x. Full text in Research Archive Show summary

  Background Melanoma incidence is increasing in many parts of the world. The main environmental risk factor is exposure to solar radiation. However, melanomas may arise also on non-sun-exposed areas (uveal and mucosal melanomas) and little is known about a possible relationship between sun exposure and melanoma on such locations. Objectives We have compared the time and latitude trends of melanoma incidence in the anorectal region and perianal skin (non-sun-exposed sites) with those of cutaneous malignant melanoma (CMM) (sun-exposed skin) to gain more information about the relationship between sun exposure and melanoma on such sites. Methods We analysed epidemiological data from the Cancer Registry of Norway for melanomas of the anorectal mucosa, perianal skin and overall CMM for the time period 1966-2007. Results We found that melanoma incidence on these shielded sites tends to decrease or remain constant over a period during which the CMM rates increase. This is true both in the North and in the South regions of Norway. Comparison of latitudinal trends of the incidence rates of CMM and melanoma on these shielded sites shows that there is no latitude gradient for melanoma of the anorectal mucosa and perianal skin, whereas there is a strong one for CMM. Conclusions The time and latitudinal trends are likely to support the assumption that melanomas on these shielded sites are not generated by ultraviolet radiation. Possible causes and significances of these trends are discussed.

• Juzeniene, Asta; Brekke, Pål; Dahlback, Arne; Andersson-Engels, Stefan; Reichrath, Jörg & Moan, Kristin [Show all 9 contributors for this article] (2011). Solar radiation and human health. Reports on progress in physics (Print). ISSN 0034-4885. 74(6). doi: 10.1088/0034-4885/74/6/066701. Full text in Research Archive
• Agostinis, Patrizia; Berg, Alf Kristian; Cengel, Keith A.; Foster, Thomas H.; Girotti, Albert W. & Gollnick, Sandra O. [Show all 17 contributors for this article] (2011). Photodynamic Therapy of Cancer: An Update. CA: A Cancer Journal for Clinicians. ISSN 0007-9235. 61(4), p. 250–281. doi: 10.3322/caac.20114. Full text in Research Archive
• Kwitniewski, Mateusz; Moan, Johan Emilian & Juzeniene, Asta (2011). Metabolic-targeted therapy with dichloroacetate (DCA): a novel treatment strategy to improve the outcome of photodynamic therapy. Photochemical and Photobiological Sciences. ISSN 1474-905X. 10(1), p. 25–28. doi: 10.1039/c0pp00193g. Full text in Research Archive
• Grant, William B.; Juzeniene, Asta & Moan, Johan Emilian (2011). Health benefit of increased serum 25(OH)D levels from oral intake and ultraviolet-B irradiance in the Nordic countries. Scandinavian Journal of Public Health. ISSN 1403-4948. 39(1), p. 70–78. doi: 10.1177/1403494810382473. Full text in Research Archive
• Morrow, Desmond I.J.; McCarron, Paul A.; Woolfson, A. David; Juzenas, Petras; Juzeniene, Asta & Moan, Johan Emilian [Show all 8 contributors for this article] (2010). Influence of penetration enhancers on topical delivery of 5-aminolevulinic acid from bioadhesive patches. Journal of Pharmacy and Pharmacology (JPP). ISSN 0022-3573. 62(6), p. 685–695. doi: 10.1211/jpp/62.06.0004. Full text in Research Archive
• Mikolajewska, Patrycja Maria; Donnelly, Ryan F.; Garland, M.J.; Morrow, Desmond I.J.; Singh, T.R.R. & Iani, Vladimir [Show all 8 contributors for this article] (2010). Microneedle Pre-treatment of Human Skin Improves 5-Aminolevulininc Acid (ALA)- and 5-Aminolevulinic Acid Methyl Ester (MAL)-Induced PpIX Production for Topical Photodynamic Therapy Without Increase in Pain or Erythema. Pharmaceutical Research. ISSN 0724-8741. 27(10), p. 2213–2220. doi: 10.1007/s11095-010-0227-2. Full text in Research Archive
• Cicarma, Emanuela; Juzeniene, Asta; Porojnicu, Alina Carmen; Bruland, Øyvind & Moan, Johan Emilian (2010). Latitude gradient for melanoma incidence by anatomic site and gender in Norway 1966-2007. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 101(2), p. 174–178. doi: 10.1016/j.jphotobiol.2010.04.002. Full text in Research Archive
• Cicarma, Emanuela; Mork, Cato; Porojnicu, Alina Carmen; Juzeniene, Asta; Tam, Tran Thi Thu & Dahlback, Arne [Show all 7 contributors for this article] (2010). Influence of narrowband UVB phototherapy on vitamin D and folate status. Experimental Dermatology. ISSN 0906-6705. 19(8), p. E67–E72. doi: 10.1111/j.1600-0625.2009.00987.x. Full text in Research Archive
• Morrow, Desmond I.J.; McCarron, Paul A.; Woolfson, A. David; Juzenas, Petras; Juzeniene, Asta & Iani, Vladimir [Show all 8 contributors for this article] (2010). Novel patch-based systems for the localised delivery of ALA-esters. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 101(1), p. 59–69. doi: 10.1016/j.jphotobiol.2010.06.012. Full text in Research Archive
• Juzeniene, Asta; Stokke, Kjell Torgeir; Thune, Per & Moan, Johan Emilian (2010). Pilot study of folate status in healthy volunteers and in patients with psoriasis before and after UV exposure. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 101(2), p. 111–116. doi: 10.1016/j.jphotobiol.2010.01.013. Full text in Research Archive
• Morrow, Desmond I.J.; McCarron, Paul A.; Woolfson, A. David; Juzenas, Petras; Juzeniene, Asta & Iani, Vladimir [Show all 8 contributors for this article] (2010). Hexyl Aminolaevulinate Is a More Effective Topical Photosensitiser Precursor than Methyl Aminolaevulinate and 5-Aminolaevulinic Acids When Applied in Equimolar Doses. Journal of Pharmaceutical Sciences. ISSN 0022-3549. 99(8), p. 3486–3498. doi: 10.1002/jps.22116. Full text in Research Archive
• Juzeniene, Asta; Ma, Li-Wei; Kwitniewski, Mateusz; Polev, GA; Lagunova, Zoya & Dahlback, Arne [Show all 7 contributors for this article] (2010). The seasonality of pandemic and non-pandemic influenzas: the roles of solar radiation and vitamin D. International Journal of Infectious Diseases. ISSN 1201-9712. 14(12), p. E1099–E1105. doi: 10.1016/j.ijid.2010.09.002. Full text in Research Archive
• Moan, Johan Emilian; Porojnicu, Alina Carmen; Dahlback, Arne; Grant, William B. & Juzeniene, Asta (2010). Where the sun does not shine: Is sunshine protective against melanoma of the vulva? Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 101(2), p. 179–183. doi: 10.1016/j.jphotobiol.2010.03.003. Full text in Research Archive
• Juzeniene, Asta; Juzenas, Petras; Iani, Vladimir & Moan, Johan Emilian (2010). Reflectance spectroscopy and fluorescein angiography applied to assess photodynamic response in healthy mouse skin treated with topical hexylaminolevulinate. Photodiagnosis and Photodynamic Therapy. ISSN 1572-1000. 7(4), p. 239–245. doi: 10.1016/j.pdpdt.2010.07.001. Full text in Research Archive
• Juzenas, Petras & Juzeniene, Asta (2010). Reduction of cutaneous photosensitivity by application of ointment containing ferrous or cobaltous ions concomitant with the use of topical protoporphyrin IX precursors. Photodiagnosis and Photodynamic Therapy. ISSN 1572-1000. 7(3), p. 152–157. doi: 10.1016/j.pdpdt.2010.06.003. Full text in Research Archive
• Generalov, Roman; Lukoseviciute, Simona; Juzeniene, Asta & Juzenas, Petras (2010). Cytotoxicity and Phototoxicity of Red Fluorescent Nontargeted Quantum Dots. IEEE Journal of Selected Topics in Quantum Electronics. ISSN 1077-260X. 16(4), p. 997–1003. doi: 10.1109/JSTQE.2009.2034387. Full text in Research Archive
• Cicarma, E.; Porojnicu, A. C.; Lagunova, Z.; Dahlback, Arne; Juzeniene, Asta & Moan, Johan Emilian (2009). Sun and sun beds: inducers of vitamin D and skin cancer. Anticancer Research. ISSN 0250-7005. 29(9). Full text in Research Archive
• Juzeniene, A; Setlow, R; Porojnicu, A; Steindal, Arnfinn Hykkerud & Moan, Johan (2009). Development of different human skin colors: A review highlighting photobiological and photobiophysical aspects. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 96(2), p. 93–100. doi: 10.1016/j.jphotobiol.2009.04.009. Full text in Research Archive
• Mikolajewska, Patrycja Maria; Juzeniene, Asta; Iani, Vladimir; Sollund, Håvar Andreas; Norsang, G & Moan, Johan Emilian (2009). A pilot study comparing the pain sensations during PpIX build-up and clearance phases. Proceedings of SPIE, the International Society for Optical Engineering. ISSN 0277-786X. 7380. doi: 10.1117/12.822949. Full text in Research Archive
• Tam, TTT; Tam, Tran Thi Thu; Juzeniene, A; Steindal, Arnfinn Hykkerud; Iani, V & Moan, Johan (2009). Photodegradation of 5-methyltetrahydrofolate in the presence of Uroporphyrin. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 94(3), p. 201–204. doi: 10.1016/j.jphotobiol.2008.12.003. Full text in Research Archive
• Moan, Johan Emilian; Mikolajewska, Patrycja Maria; Juzeniene, Asta & Cicarma, Emanuela (2009). Lasers and non-coherent light in dermatological applications. In Martinsen, Ørjan Grøttem & Jensen, Øystein (Ed.), An anthology of developments in clinical engineering and bioimpedance. Medisinsk-teknisk avdelings forlag. ISSN 9788299162692. Full text in Research Archive
• Cicarma, Emanuela; Tuorkey, M; Juzeniene, Asta; Ma, LW & Moan, Johan Emilian (2009). Calcitriol treatment improves methyl aminolaevulinate-based photodynamic therapy in human squamous cell carcinoma A431 cells. British Journal of Dermatology. ISSN 0007-0963. 161(2), p. 413–418. doi: 10.1111/j.1365-2133.2009.09180.x. Full text in Research Archive

View all works in NVA

• Juzeniene, Asta; Baum, Richard Paul; Bruland, Øyvind & Larsen, Roy (2023). Targeted Alpha Particle Therapy in Oncology. Frontiers in Medicine. ISBN 9782832519837. 186 p. Full text in Research Archive

View all works in NVA

• Tornes, Anna Julie Kjøl; Stenberg, Vilde Yuli; Repetto, Llamazares Ada H.V.; Larsen, Roy Hartvig & Juzeniene, Asta (2023). Fractionated therapy of the PSMA-targeted radioligand 212Pb-AB001 significantly delays tumor growth. Full text in Research Archive
• Bruland, Øyvind; Larsen, Roy Hartvig; Baum, Richard Paul & Juzenienne, Asta (2023). Editorial: Targeted alpha particle therapy in oncology. Frontiers in Medicine. 10. doi: 10.3389/fmed.2023.1165747. Full text in Research Archive
• Eldri, Scheie; Juzeniene, Asta & Moan, Johan Emilian (2015). Derfor har vi forskjellig hudfarge! Naturfag. ISSN 1504-4564. p. 68–71. Full text in Research Archive
• Moan, Johan Emilian & Juzeniene, Asta (2014). Mørketiden går på helsen løs. Aftenposten Viten. ISSN 2464-3033. Full text in Research Archive
• Grigalavicius, Mantas; Juzeniene, Asta; Hamre, Børge; Stamnes, Jakob J.; Jani, I.V & Moan, Johan Emilian (2013). UVA-induced optical skin changes. Full text in Research Archive
• Juzeniene, Asta; Grant, William B. & Moan, Johan Emilian (2012). Reply to "Vitamin D supplementation did not prevent influenza-like illness as diagnosed retrospectively by questionnaires in subjects participating in randomized clinical trials". Scandinavian Journal of Infectious Diseases. ISSN 0036-5548. 44(9), p. 712–713. doi: 10.3109/00365548.2012.658580. Full text in Research Archive
• Moan, Kristin; Moan, Johan Emilian & Juzeniene, Asta (2011). Sol - og psykisk helse. Dagens medisin. ISSN 1501-4290. Full text in Research Archive
• Juzeniene, Asta; Ma, Li Wei; Kwitniewski, Mateusz; Polev, Georgy A.; Lagunova, Zoya & Dahlback, Arne [Show all 7 contributors for this article] (2011). Influenza, solar radiation and vitamin D. Anticancer Research. ISSN 0250-7005. 31(4), p. 1502–1502. Full text in Research Archive
• Moan, Johan Emilian; Juzeniene, Asta; Porojnicu, Alina Carmen & Dahlback, Arne (2011). Is sunshine and vitamin d protective against melanoma on shielded sites? Anticancer Research. ISSN 0250-7005. 31(4), p. 1502–1502. Full text in Research Archive
• Grant, William B.; Juzeniene, Asta; Lagunova, Zoya; Porojnicu, Alina Carmen & Moan, Johan Emilian (2011). Vitamin D levels in Norway may be inadequate to reduce risk of breast cancer. International Journal of Cancer. ISSN 0020-7136. 128(9), p. 2249–2250. doi: 10.1002/ijc.25552. Full text in Research Archive
• Moan, Johan Emilian & Juzeniene, Asta (2010). Solar radiation and human health. Journal of Photochemistry and Photobiology. B: Biology. ISSN 1011-1344. 101(2), p. 109–110. doi: 10.1016/j.jphotobiol.2010.08.004. Full text in Research Archive
• Moan, Johan Emilian & Juzeniene, Asta (2010). Sol, D-vitamin og MS. MS-bladet. ISSN 1500-659X. p. 10–11. Full text in Research Archive
• Grant, William B.; Moan, Johan Emilian; Micu, Emanuela; Porojnicu, Alina Carmen & Juzeniene, Asta (2010). Similarities in solar ultraviolet irradiance and other environmental factors may explain much of the family link between uveal melanoma and other cancers. Familial Cancer. ISSN 1389-9600. 9(4), p. 659–660. doi: 10.1007/s10689-010-9374-1. Full text in Research Archive
• Juzeniene, Asta; Iani, Vladimir; Kaliszewski, Miron; Bugaj, Andrzej & Moan, Johan Emilian (2009). Clearance of protoporphyrin IX from WiDr human colon adenocarcinoma cells and from normal mouse skin after application of 5-aminolevulinic acid. Full text in Research Archive

View all works in NVA